Synact Pharma | VD och ordförande om ny strategisk plan – February 2, 2024

SynAct Pharma sätter ny strategi för 2024 – February 2, 2024

Resolving Inflammation Without Immunosuppression

Most available treatments used to treat inflammation suppress the immune system which can lead to a heightened risk of serious safety issues. Inflammation resolution strategies seek to provide both anti-inflammatory and pro-resolving activity without suppressing the immune system.

Harnessing the Melanocortin System to Resolve Inflammation

SynAct harnesses the melanocortin system to stimulate both anti-inflammatory and inflammation resolution mechanisms to resolve excessive inflammation safely without suppressing the immune system’s ability to respond to new infections or injuries.

Resomelagon (AP1189)

An Oral Selective Melanocortin Agonist

Our lead drug candidate resomelagon (AP1189) is a once-daily oral selective melanocortin agonist that selectively stimulates melanocortin receptors to help the body resolve inflammation. Resomelagon (AP1189) is being evaluated in rheumatoid arthritis (RA), idiopathic membranous nephropathy (iMN) and respiratory insufficiency caused by viruses like COVID-19.

SynAct Pharma AB published its year-end report for 2023 on February 23 at 07.30 CET.

Conference call and online presentation: the same day at 15.00 CET.

A MESSAGE FROM OUR CEO

“We have excellent opportunities before us, and we remain focused on delivering patient, company and shareholder value.”